BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
49.08
-1.15 (-2.29%)
At close: Aug 22, 2025, 4:00 PM
49.60
+0.52 (1.06%)
After-hours: Aug 22, 2025, 7:32 PM EDT

Company Description

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.

The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.
BridgeBio Pharma logo
CountryUnited States
Founded2015
IPO DateJun 27, 2019
IndustryBiotechnology
SectorHealthcare
Employees730
CEONeil Kumar

Contact Details

Address:
3160 Porter Drive, Suite 250
Palo Alto, California 94304
United States
Phone650 391 9740
Websitebridgebio.com

Stock Details

Ticker SymbolBBIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001743881
CUSIP Number10806X102
ISIN NumberUS10806X1028
SIC Code2834

Key Executives

NamePosition
Dr. Eric Michael David J.D., M.D., Ph.D.Chief Executive Officer of Gene Therapy
Dr. Neil Kumar Ph.D.Co-Founder, Chief Executive Officer and Director
Dr. Thomas Trimarchi Ph.D.Chief Financial Officer and President
Dr. Charles J. Homcy M.D.Co-Founder, Chairman of Pharmaceuticals and Independent Lead Director
Dr. Frank P. McCormick Ph.D.Co-Founder, Chairman of Oncology and Director
Maricel M. ApuliChief Accounting Officer
Dr. Uma Sinha Ph.D.Chief Scientific Officer
Dr. Richard H. Scheller Ph.D.Chairman of Research and Development
Eli M. Wallace Ph.D.Chief Scientific Officer of Oncology
Matthew Outten CPC, MBAChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Aug 21, 2025144Filing
Aug 20, 2025144Filing
Aug 18, 20253Initial statement of beneficial ownership of securities
Aug 18, 2025144Filing
Aug 14, 2025SCHEDULE 13D/AFiling
Aug 11, 2025144Filing
Aug 8, 2025144Filing
Aug 5, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 5, 202510-QQuarterly Report
Aug 5, 2025144Filing